Welcome to our dedicated page for WORK Medical Technology Group news (Ticker: WOK), a resource for investors and traders seeking the latest updates and insights on WORK Medical Technology Group stock.
WORK Medical Technology Group LTD (WOK) is a leading manufacturer of critical medical consumables including face masks, intubation accessories, and infection control products. This news hub provides investors and healthcare industry professionals with timely updates on corporate developments, financial performance, and operational milestones.
Access official press releases and market analyses covering earnings announcements, regulatory updates, product innovations, and strategic partnerships. Our curated news collection enables stakeholders to track WOK's position in the competitive medical device sector while monitoring factors influencing long-term growth potential.
Key content categories include quarterly financial disclosures, manufacturing capacity expansions, quality certification achievements, and distribution network developments. All materials are sourced from verified channels to ensure reliability for investment research and sector analysis.
Bookmark this page for centralized access to WOK's latest business updates, and check regularly for new developments impacting the medical consumables market. For historical context, cross-reference news items with the company's SEC filings and annual reports available through Stock Titan's financial database.
WORK Medical (Nasdaq: WOK) announced that its subsidiary Neologics Bioscience entered a service agreement with GemPharmatech on Nov 4, 2025 to provide antibody R&D testing and in vitro validation services.
Under the Agreement, GemPharmatech will pay US$114,000 in total for services performed under work orders. WORK Medical previously invested $1.0 million in Neologics on Oct 21, 2025 and, as of Oct 29, 2025, holds a 10% equity interest following Delaware shareholder registration. Neologics operates an R&D lab in San Diego and focuses on AI-integrated preclinical drug screening and target discovery.
WORK Medical (NASDAQ: WOK) agreed to invest US$1 million in Neologics Bioscience to acquire a 10% equity interest via newly issued shares, on a post-investment basis. The transaction raises Neologics's total capital reserve to US$10 million and leaves the existing shareholder with a 90% stake.
WORK Medical gains governance rights tied to its 10% holding, a right of first refusal on future equity offers, and expects Neologics to complete registration and issue an equity certificate within 20 working days. Proceeds will support operations, R&D, market expansion, and hiring.
WORK Medical Technology Group (Nasdaq: WOK) will effect a 1-for-100 reverse stock split effective October 21, 2025, with Class A shares trading on a post-split basis from market open that day under the existing ticker WOK and new CUSIP G9767H117.
The split was approved by shareholders and the board to regain compliance with Nasdaq Rule 5550(a)(2). Fractional shares will be rounded up to the next whole share. Outstanding Class A shares will fall from approximately 96.00 million to 960,000; Class B shares will fall from approximately 7.59 million to 76,000.
WORK Medical Technology Group (NASDAQ: WOK) received a Nasdaq determination letter dated October 9, 2025 notifying the company of a delisting due to its Class A ordinary shares having a closing bid price of $0.10 or less for ten consecutive trading days ending October 8, 2025.
Unless appealed, trading will be suspended at the open of business on October 20, 2025 and a Form 25-NSE will be filed to remove the company’s securities from Nasdaq. The company may request a hearing by October 16, 2025; a hearing request will stay the suspension. The company plans to appeal by October 16 and said it will consider options to regain compliance, including a possible reverse share split.
WORK Medical (Nasdaq: WOK) received a Nasdaq notification dated October 7, 2025 granting an additional 180-calendar-day compliance period to regain the minimum bid price under Nasdaq Listing Rule 5550(a)(2).
The company’s initial 180-day cure period expired October 6, 2025; the new deadline is April 6, 2026. To regain compliance, WOK must achieve a closing bid of $1.00 per share for at least 10 consecutive business days (Nasdaq may require up to 20 days depending on factors).
The company said it intends to cure the deficiency, including potentially implementing a reverse stock split. Trading of Class A ordinary shares on Nasdaq under WOK continues with no immediate delisting action.
WORK Medical Technology Group (NASDAQ:WOK) has announced a registered direct offering of 38,999,334 Class A ordinary shares at $0.075 per share, aiming to raise approximately $2.9 million in gross proceeds. The offering includes pre-funded warrants with an exercise price of $0.0005 per share.
The transaction, expected to close around September 26, 2025, is being conducted under a shelf registration statement on Form F-3. Univest Securities, LLC is serving as the sole placement agent for this offering.
WORK Medical Technology Group (NASDAQ:WOK) has announced a strategic partnership with the Hong Kong Web3.0 Standardization Association Limited to innovate in blockchain and Real-world Asset (RWA) solutions. The collaboration focuses on three key areas: asset tokenization, joint investment vehicles, and RWA technology development.
As part of the agreement, WORK Medical has been appointed as a Vice President Unit of the Association. The partnership aims to leverage WORK Medical's status as a Nasdaq-listed medical device manufacturer and the Association's Web3.0 expertise to develop compliant blockchain solutions for asset tokenization and cross-chain transactions.
WORK Medical Technology Group (NASDAQ:WOK) has announced a strategic partnership with the Wuxi Branch of Ruijin Hospital-Shanghai Jiao Tong University School of Medicine (Xin Rui Hospital) to develop AI-powered medical solutions. Through its subsidiary Work Hangzhou, the company will support Xin Rui Hospital in advancing hospital informatization and AI applications.
The collaboration aims to integrate AI technology with Xin Rui Hospital's multimodal medical resources, including text, imaging, and laboratory data. Work Hangzhou plans to enhance its multimodal universal medical AI solution by expanding from single-image data to complex multimodal data. The partnership will focus on data governance, model training, and clinical practice implementation.
WORK Medical Technology Group (Nasdaq: WOK) has successfully closed its registered offering of 10 million ordinary units at $0.50 per unit, raising gross proceeds of $5.0 million. Each unit includes one Class A ordinary share and two warrants (Series A and B) to purchase additional shares at $1.00 exercise price. Series A warrants expire in 12 months, while Series B warrants expire in 3 months.
The company plans to use the proceeds for upgrading production equipment, R&D investments, improving internal control systems, ensuring compliance with U.S. GAAP and Sarbanes-Oxley Act, and working capital. Univest Securities served as the sole book-running manager for this firm commitment offering.
FAQ
What is the current stock price of WORK Medical Technology Group (WOK)?
What is the market cap of WORK Medical Technology Group (WOK)?
